Immunoterapia del carcinoma renale metastatico con interleuchina-2 secondo uno schema di somministrazione sottocutanea di breve durata

Translated title of the contribution: Immunotherapy of metastatic renal cell cancer by a short subcutaneous injection of interleukin-2

P. Lissoni, S. Barni, A. Ardizzoia, F. Paolorossi, G. Tancini, M. Andres, P. Favini, E. Scardino, F. Rocco

Research output: Contribution to journalArticle

Abstract

It has been shown that low-dose subcutaneous (SC) IL-2 exerts an efficacy similar to that described for the intravenous high-doses in the immunotherapy of metastatic renal cell cancer (RCC). However, it remains to be established which could be the optimal duration of treatment. The most common schedules with subcutaneous IL-2 are generally consisting of 6 weeks of therapy, with an IL-2 dose of about 6 milion IU/day. This study was performed to evaluate the efficacy of IL-2 subcutaneous immunotherapy with a duration of 4 weeks only. The study included 13 evaluable metastatic RCC patients. IL-2 has been injected subcutaneously at 6 million IU/day for 6 days/week for 4 weeks, by repeating a second cycle in nonprogressing patients after a 21-day rest period. Objective tumor regressions were achieved in 3/13 (23%) patients consisting of CR in 1 and PR in the other 2. Stable disease was obtained in other 6 patients. This preliminary study would suggest that a shorter dose-matched S.C.IL-2 immunotherapy may have a similar therapeutic efficacy in metastatic RCC. Therefore, the 4-week IL-2 S.C. immunotherapy, instead of the 6-week schedule could become the standard immunotherapeutic schedule, with following decreased cost and toxicity.

Translated title of the contributionImmunotherapy of metastatic renal cell cancer by a short subcutaneous injection of interleukin-2
Original languageItalian
Pages (from-to)159-162
Number of pages4
JournalArchivio Italiano di Urologia e Andrologia
Volume69
Issue number3
Publication statusPublished - 1997

ASJC Scopus subject areas

  • Nephrology
  • Urology

Fingerprint Dive into the research topics of 'Immunotherapy of metastatic renal cell cancer by a short subcutaneous injection of interleukin-2'. Together they form a unique fingerprint.

  • Cite this

    Lissoni, P., Barni, S., Ardizzoia, A., Paolorossi, F., Tancini, G., Andres, M., Favini, P., Scardino, E., & Rocco, F. (1997). Immunoterapia del carcinoma renale metastatico con interleuchina-2 secondo uno schema di somministrazione sottocutanea di breve durata. Archivio Italiano di Urologia e Andrologia, 69(3), 159-162.